公司資料
Prelude Therapeutics 股價、新聞與催化劑
- 股票代碼:
- PRLD
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
6.63 USD (+2.00%)
收盤價
最後更新: 2026年8月21日
279M USD
市值
股價為何變動
As of Aug 21, 2026, PRLD closed up 2.00% at $6.63. No new same-company headline was identified in the current news window.
公司概覽
Precision Oncology Company
Prelude Therapeutics develops medicines for validated cancer targets using selective degradation and mutant-specific inhibition.
PRT12396
PRT12396 selectively inhibits mutant JAK2V617F and is in Phase 1 development for polycythemia vera and myelofibrosis.
PRT13722
PRT13722 is an oral KAT6A degrader intended for hormone-receptor-positive breast cancer and other KAT6A-dependent tumors.
Degrader Antibody Conjugates
Prelude is also applying its targeted protein degradation expertise to degrader antibody conjugates, including programs directed at mutant calreticulin in myeloproliferative neoplasms.
未來催化劑
- Initiation of a Phase 1 study of PRT13722 in hormone-receptor-positive breast cancer in the fourth quarter of 2026, pending IND clearance.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。